Matthew P Kosloski1, Haoyu Wang2, David Pugatch3, Federico J Mensa3, Edward Gane4, Eric Lawitz5, Thomas C Marbury6, Richard A Preston7,8, Jens Kort9, Wei Liu10. 1. Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA. 2. Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA. 3. Infectious Diseases, AbbVie Inc., North Chicago, IL, USA. 4. University of Auckland, Auckland, New Zealand. 5. Texas Liver Institute, University of Texas Health, San Antonio, TX, USA. 6. Orlando Clinical Research Center, Orlando, FL, USA. 7. Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA. 8. Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. 9. Medical Affairs, AbbVie Inc., North Chicago, IL, USA. 10. Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA. wei.liu@abbvie.com.
Abstract
PURPOSE: This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection. METHODS: HCV-negative subjects with normal hepatic function, or with mild (Child-Pugh [CP]-A), moderate (CP-B), or severe (CP-C) hepatic impairment received single doses of pibrentasvir 120 mg alone or with glecaprevir 200 mg or 300 mg (n = 6/functional group/dose). Plasma pharmacokinetics and protein binding were evaluated. Doses were separated by ≥ 14 days of washout. RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was ≤ 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C). For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (≤ 12% difference). Pibrentasvir 120 mg alone AUC increased 51% (CP-A), 31% (CP-B), and to 5.2-fold (CP-C). The unbound fraction of glecaprevir was higher in CP-C subjects than normal subjects and pibrentasvir protein binding was similar across groups. The most common adverse event was headache; no events were serious. CONCLUSION: This study supported evaluation of the glecaprevir 300 mg with pibrentasvir 120-mg combination in HCV-infected subjects with CP-A hepatic impairment without dose adjustment. Elevated glecaprevir and/or pibrentasvir exposures are expected in HCV-infected patients with CP-B or CP-C hepatic impairment.
PURPOSE: This study characterized the effects of hepatic impairment on the pharmacokinetics and safety of glecaprevir and pibrentasvir, two direct-acting antivirals used for treatment of chronic HCV infection. METHODS: HCV-negative subjects with normal hepatic function, or with mild (Child-Pugh [CP]-A), moderate (CP-B), or severe (CP-C) hepatic impairment received single doses of pibrentasvir 120 mg alone or with glecaprevir 200 mg or 300 mg (n = 6/functional group/dose). Plasma pharmacokinetics and protein binding were evaluated. Doses were separated by ≥ 14 days of washout. RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was ≤ 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C). For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (≤ 12% difference). Pibrentasvir 120 mg alone AUC increased 51% (CP-A), 31% (CP-B), and to 5.2-fold (CP-C). The unbound fraction of glecaprevir was higher in CP-C subjects than normal subjects and pibrentasvir protein binding was similar across groups. The most common adverse event was headache; no events were serious. CONCLUSION: This study supported evaluation of the glecaprevir 300 mg with pibrentasvir 120-mg combination in HCV-infected subjects with CP-A hepatic impairment without dose adjustment. Elevated glecaprevir and/or pibrentasvir exposures are expected in HCV-infectedpatients with CP-B or CP-C hepatic impairment.
Entities:
Keywords:
Glecaprevir; Hepatic impairment; Hepatitis C virus; Pharmacokinetics; Pibrentasvir
Authors: G Zollner; P Fickert; R Zenz; A Fuchsbichler; C Stumptner; L Kenner; P Ferenci; R E Stauber; G J Krejs; H Denk; K Zatloukal; M Trauner Journal: Hepatology Date: 2001-03 Impact factor: 17.425
Authors: Amit Khatri; Rajeev M Menon; Thomas C Marbury; Eric J Lawitz; Thomas J Podsadecki; Victoria M Mullally; Bifeng Ding; Walid M Awni; Barry M Bernstein; Sandeep Dutta Journal: J Hepatol Date: 2015-06-10 Impact factor: 25.083
Authors: Albader Albarmawi; David Czock; Annika Gauss; Robert Ehehalt; Justo Lorenzo Bermejo; Jürgen Burhenne; Tom M Ganten; Peter Sauer; Walter E Haefeli Journal: Br J Clin Pharmacol Date: 2014-01 Impact factor: 4.335
Authors: Vijay R More; Qiuqiong Cheng; Ajay C Donepudi; David B Buckley; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt Journal: Drug Metab Dispos Date: 2013-03-05 Impact factor: 3.922
Authors: Elise J Smolders; Anouk M E Jansen; Peter G J Ter Horst; Jürgen Rockstroh; David J Back; David M Burger Journal: Clin Pharmacokinet Date: 2019-10 Impact factor: 6.447